THE ROLE OF NO SYNTHESIS CORRECTION IN PREVENTION OF CARDIOVASCULAR HYPERTENSIVE REMODELING
Abstract
Comparative study of preventive effects of two beta-blocking drugs with different mode of action was performed on SHRSP and WKY rats. Morphological and functional parameters – blood pressure, endothelium-dependent vascular relaxation, plasma level of nitric oxide stable metabolites (nitrite/nitrate), cardiac hyperthrophy and vascular remodeling were monitored during chronic nebivolol and metoprolol injection in parallel groups of rats. Nebivolol, a cardioselective beta-blocker with ancillary nitric oxide modulating and vasodilating properties exhibited more significant and stable influence on the monitored parameters than metoprolol lacking the nitric oxide modulating activity and more effectively prevented cardiovascular remodeling in experimental hypertension.
About the Authors
V. I. Buvaltsev
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
S. Y. Mashina
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
D. A. Pokidyshev
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
B. V. Smirin
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
L. A. Bayda
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
V. Y. Malyshev
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
E. B. Manukina
Научно-исследовательский институт общей патологии и патофизиологии РАМН
Russian Federation
Russian Federation
References
1. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Amer. J. Cardiol. 1979; V.44, P.959-963.
2. Parenti A; Filippi S; Amerini S et al. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J. Pharmacol. Exp. Ther. 2000, 292(2):698-703
3. Ritter JM Nebivolol: endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol. 2001, Suppl. 3:S13-16.
4. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation, 2001 104(5):511-514.
5. Broeders MA, Doevendans PA, Bekkers BC, et al.. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000, 102(6):677-684.
6. Moshage H., Kok B., Huzenga R., Jansen P. Nitrite and nitrate determination in plasma: A critical evaluation. // Clin. Chem. 1995. V. 41. P. 892-896.
7. Puddu P., Puddu G.M., Zaca F., Muscari A. Endothelial dysfunction in hypertension. Acta Cardiol., 2000, 55: 221-232.
8. Taddei S, Virdis A, Ghiadoni L et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62(2):265-284
9. Goldstein S. Beta-bloicking drugs and coronary heart disease. Cardiovasc. Drugs Ther., 1997, 11(suppl 1):219-225.
10. Falciani M, Rinaldi B, D’Agostino B et al. Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001 38(6):922-929.
11. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.J Hypertens 2001, 19(8):1429-1435
12. Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res. 2001 Feb 1;49(2):430-439.
13. Radaelli A, Mircoli L, Mori I et al. Nitric oxide-dependent vasodilation in young spontaneously hypertensive rats. // Hypertension. 1998. V. 32. P. 735-739.
14. Wu CC, Yen MH. Nitric oxide synthase in spontaneously hypertensive rats. Biomed. Sci. 1997. V. 4. P. 249-255.
15. Chou TC, Yen MH, Ding YA. Alterations of nitric oxide synthesis with aging and hypertension in rats. // Hypertension. 1998. V. 31. P. 643-648.
16. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol., 2000, 90: 244-254.
17. Colasanti M., Hisanori S. The dual personality of NO. TIPS, 2000, 21: 249-252.
18. Muller B., Kleschyov A.L., Gyorgy J.C., Stoclet J.C. Inducible NO synthase activity in blood vessels and heart: new insight into cell origin and consequences. Physiol. Res., 2000, 49: 19-26.
19. Малышев И.Ю., Манухина Е.Б. Стресс, адаптация и оксид азота. Биохимия, 1998, т.63,вып. 7, с. 992-1006.
20. Машина С.Ю., Смирин Б.В., Покидышев Д.А. и др. Роль предупреждения дефицита оксида азота в антигипертензивном эффекте адаптации к гипоксии. Известия АН. Серия биол., 2001, № 5, 579-587.
21. Tanaka H., Bassett D.R., Howley E.T. et al. Swimming training lowers the resting blood pressure in individuals with hypertension. //J. Hypertens. –1997.-V.15 P.651-657.
22. Nimaguchi K., Egashira K., Takemoto M. et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 1995, 26: 957-962.
23. Franz IW, Ketelhut R, Behr U, Tonnesmann U.J. Time course of reduction in left ventricular mass during long-term antihypertensive therapy. Hum. Hypertens. 1994, 8:191-198
24. Schobel HP, Langenfeld M, Gatzka C, Schmieder RE. Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am. Heart J., 1996, 132:1004-1009
25. L.Raij, H.Hayakawa. Blood pressure, endothelial dysfunction and target organ injury. Eur. Heart J. Vol.1 (Suppl. L), 1999, L44-L49.
26. Simko F., Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol. Res., 2000, 49: 37-46.
27. Pessina A.C. Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol. 2001 38 Suppl. 3:S33-35.
Review
For citations:
Buvaltsev V.I., Mashina S.Y., Pokidyshev D.A., Smirin B.V., Bayda L.A., Malyshev V.Y., Manukina E.B. THE ROLE OF NO SYNTHESIS CORRECTION IN PREVENTION OF CARDIOVASCULAR HYPERTENSIVE REMODELING. Russian Journal of Cardiology. 2002;(5):74-81. (In Russ.)
Views:
465
Email this article 